185 related articles for article (PubMed ID: 33014430)
21. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
22. A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.
Zhao YF; Han ML; Xiong YJ; Wang L; Fei Y; Shen X; Zhu Y; Liang ZQ
Acta Pharmacol Sin; 2018 Jun; 39(6):1034-1047. PubMed ID: 29219949
[TBL] [Abstract][Full Text] [Related]
23. [Low expression of lncRNA-GAS5 promotes epithelial-mesenchymal transition of breast cancer cells in vitro].
Ding YX; Duan KC; Chen SL
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Nov; 37(11):1427-1435. PubMed ID: 29180320
[TBL] [Abstract][Full Text] [Related]
24. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Menendez JA; Vellon L; Mehmi I; Teng PK; Griggs DW; Lupu R
Oncogene; 2005 Jan; 24(5):761-79. PubMed ID: 15592521
[TBL] [Abstract][Full Text] [Related]
25. The glycoproteins EDIL3 and MFGE8 regulate vesicle-mediated eggshell calcification in a new model for avian biomineralization.
Stapane L; Le Roy N; Hincke MT; Gautron J
J Biol Chem; 2019 Oct; 294(40):14526-14545. PubMed ID: 31358619
[TBL] [Abstract][Full Text] [Related]
26. EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer.
Ke B; Liang ZK; Li B; Wang XJ; Liu N; Liang H; Zhang RP
PeerJ; 2023; 11():e15559. PubMed ID: 37576496
[TBL] [Abstract][Full Text] [Related]
27. αvβ3 Integrin induces partial EMT independent of TGF-β signaling.
Kariya Y; Oyama M; Suzuki T; Kariya Y
Commun Biol; 2021 Apr; 4(1):490. PubMed ID: 33883697
[TBL] [Abstract][Full Text] [Related]
28. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.
Cao J; Li J; Sun L; Qin T; Xiao Y; Chen K; Qian W; Duan W; Lei J; Ma J; Ma Q; Han L
Mol Oncol; 2019 Feb; 13(2):228-245. PubMed ID: 30367545
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
31. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
Yang Q; Wang Y; Lu X; Zhao Z; Zhu L; Chen S; Wu Q; Chen C; Wang Z
Oncotarget; 2015 Feb; 6(5):3268-79. PubMed ID: 25605244
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process.
Sun T; Zhang D; Wang Z; Zhao B; Li Y; Sun X; Liu J; Wang X; Sheng J
Environ Toxicol; 2021 Sep; 36(9):1758-1764. PubMed ID: 34048126
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
34. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
[TBL] [Abstract][Full Text] [Related]
35. mRNA and protein expression of the angiogenesis-related genes EDIL3, AMOT and ECM1 in mesenchymal stem cells in psoriatic dermis.
Niu X; Chang W; Liu R; Hou R; Li J; Wang C; Li X; Zhang K
Clin Exp Dermatol; 2016 Jul; 41(5):533-40. PubMed ID: 26644074
[TBL] [Abstract][Full Text] [Related]
36. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.
Rae S; Spillane C; Blackshields G; Madden SF; Keenan J; Stordal B
Hum Cell; 2022 Sep; 35(5):1547-1559. PubMed ID: 35794446
[TBL] [Abstract][Full Text] [Related]
37. Identification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion.
Lee JE; Moon PG; Cho YE; Kim YB; Kim IS; Park H; Baek MC
J Proteomics; 2016 Jan; 131():17-28. PubMed ID: 26463135
[TBL] [Abstract][Full Text] [Related]
38. LncRNA GAS5 enhances tumor stem cell-like medicated sensitivity of paclitaxel and inhibits epithelial-to-mesenchymal transition by targeting the miR-18a-5p/STK4 pathway in prostate cancer.
Lu TT; Tao X; Li HL; Gai L; Huang H; Li F
Asian J Androl; 2022; 24(6):643-652. PubMed ID: 35295003
[TBL] [Abstract][Full Text] [Related]
39. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Changes in the Expression Pattern of EDIL3 in Different Grades of Endometrial Cancer.
Oplawski M; Dziobek K; Zmarzły N; Grabarek B; Tomala B; Leśniak E; Adwent I; Januszyk P; Dąbruś D; Boroń D
Curr Pharm Biotechnol; 2019; 20(6):483-488. PubMed ID: 30961491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
